JP2023501445A - 免疫治療のためのブロモドメイン含有タンパク質４（ｂｒｄ４）を標的とする化学修飾されたオリゴヌクレオチド - Google Patents

免疫治療のためのブロモドメイン含有タンパク質４（ｂｒｄ４）を標的とする化学修飾されたオリゴヌクレオチド Download PDF

Info

Publication number
JP2023501445A
JP2023501445A JP2022526470A JP2022526470A JP2023501445A JP 2023501445 A JP2023501445 A JP 2023501445A JP 2022526470 A JP2022526470 A JP 2022526470A JP 2022526470 A JP2022526470 A JP 2022526470A JP 2023501445 A JP2023501445 A JP 2023501445A
Authority
JP
Japan
Prior art keywords
cells
nucleic acid
molecule
intasyl
brd4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501445A5 (https=
Inventor
カルディア，ジェームズ
キースリング，ロルフ
メリエフ，イェロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phio Pharmaceuticals Corp
Original Assignee
Phio Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phio Pharmaceuticals Corp filed Critical Phio Pharmaceuticals Corp
Publication of JP2023501445A publication Critical patent/JP2023501445A/ja
Publication of JP2023501445A5 publication Critical patent/JP2023501445A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022526470A 2019-11-08 2020-11-06 免疫治療のためのブロモドメイン含有タンパク質４（ｂｒｄ４）を標的とする化学修飾されたオリゴヌクレオチド Pending JP2023501445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932813P 2019-11-08 2019-11-08
US62/932,813 2019-11-08
PCT/US2020/059512 WO2021092464A2 (en) 2019-11-08 2020-11-06 Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy

Publications (2)

Publication Number Publication Date
JP2023501445A true JP2023501445A (ja) 2023-01-18
JP2023501445A5 JP2023501445A5 (https=) 2023-11-14

Family

ID=73699423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526470A Pending JP2023501445A (ja) 2019-11-08 2020-11-06 免疫治療のためのブロモドメイン含有タンパク質４（ｂｒｄ４）を標的とする化学修飾されたオリゴヌクレオチド

Country Status (6)

Country Link
US (1) US20230002766A1 (https=)
EP (1) EP4055167A2 (https=)
JP (1) JP2023501445A (https=)
CN (1) CN115135765A (https=)
CA (1) CA3160657A1 (https=)
WO (1) WO2021092464A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
US12544344B2 (en) 2017-04-19 2026-02-10 Phio Pharmaceuticals Corp. Topical delivery of nucleic acid compounds
AU2019239971B2 (en) * 2018-03-21 2025-09-11 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
EP4282963A1 (en) * 2022-05-23 2023-11-29 Eberhard Karls Universität Tübingen, Medizinische Fakultät Nucleic acid modified biological cell with expansion-dependent gene expression
WO2024010524A1 (en) * 2022-07-05 2024-01-11 Agency For Science, Technology And Research Oligonucleotides
WO2025117786A1 (en) * 2023-11-28 2025-06-05 Phio Pharmaceuticals Corp. Enhanced combination immune checkpoint inhibition therapy utilizing rnai

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592146A2 (en) * 2011-11-14 2013-05-15 Silenseed Ltd Methods and compositions for treating prostate cancer
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4201860A (en) 1978-05-09 1980-05-06 Bristol-Myers Company Purine derivatives
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5082936A (en) 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
JPH05503952A (ja) 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
EP0491829B1 (en) 1989-09-08 1997-06-04 Alpha Beta Technology, Inc. Composition for immune system activation
WO1992003568A1 (en) 1990-08-13 1992-03-05 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
CA2040374C (en) 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
EP0547142A1 (en) 1990-08-28 1993-06-23 Epoch Pharmaceuticals, Inc. Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule
GB9022560D0 (en) 1990-10-17 1990-11-28 G B Biotechnology Limited Processing of waste
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5214135A (en) 1991-08-30 1993-05-25 Chemgenes Corporation N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
US5525719A (en) 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5428149A (en) 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5652359A (en) 1993-12-02 1997-07-29 Epoch Pharmaceuticals, Inc. Oligonucleotides containing n-methyl thiolated bases having antiviral activity
US5646126A (en) 1994-02-28 1997-07-08 Epoch Pharmaceuticals Sterol modified oligonucleotide duplexes having anticancer activity
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
AUPN398295A0 (en) 1995-07-05 1995-07-27 Carlton And United Breweries Limited Chemical compounds and processes for their production
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
US8017742B2 (en) 1999-11-10 2011-09-13 Japan Science And Technology Agency Gene carrier
US20040072785A1 (en) 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US7098030B2 (en) 1999-12-31 2006-08-29 Mirus Bio Corporation Polyampholytes for delivering polyions to a cell
JP5154728B2 (ja) 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
WO2002012348A2 (en) 2000-08-03 2002-02-14 Abac R & D Gmbh Isolation of glucan particles and uses thereof
US6476003B1 (en) 2000-11-06 2002-11-05 Immusonic, Inc. Method for preparing small particle size glucan in a dry material
FR2818642B1 (fr) 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7786094B2 (en) 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US20030157030A1 (en) 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
DE10302421A1 (de) 2003-01-21 2004-07-29 Ribopharma Ag Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
US20050026286A1 (en) 2003-03-05 2005-02-03 Jen-Tsan Chi Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
US20060178327A1 (en) 2003-05-30 2006-08-10 Yeung Wah Hin A Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20050265957A1 (en) 2004-04-08 2005-12-01 Monahan Sean D Polymerized formamides for use in delivery of compounds to cells
EP2338332B1 (en) 2004-05-20 2014-02-12 Eden Research Plc Hollow glucan particle or cell wall particle encapsulating a terpene component
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
ATE526991T1 (de) 2005-10-24 2011-10-15 Univ Massachusetts Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
WO2007084797A1 (en) 2006-01-23 2007-07-26 Abbott Laboratories Chemically modified polycation polymer for sirna delivery
EP1986675A2 (en) * 2006-02-24 2008-11-05 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
US9878043B2 (en) 2006-06-23 2018-01-30 Engeneic Molecular Delivery Pty Ltd Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
US20080039415A1 (en) 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
AU2007299705B2 (en) 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US20090043367A1 (en) 2007-08-09 2009-02-12 Yitzhak Zilberman Apparatus and methods for removing an electronic implant from a body
CA2713379A1 (en) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
CA2715289C (en) 2008-02-11 2019-12-24 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP2342340A1 (en) * 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
MX354217B (es) * 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
EP3664817A4 (en) * 2017-08-07 2021-09-22 Phio Pharmaceuticals Corp. CHEMICALLY MODIFIED OLIGONUCLEOTIDES
WO2021138537A1 (en) * 2019-12-31 2021-07-08 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592146A2 (en) * 2011-11-14 2013-05-15 Silenseed Ltd Methods and compositions for treating prostate cancer
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MELIEF J. ET AL., JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol. 7 (Suppl 1):282, JPN6024042670, 2019, pages 119 - 222, ISSN: 0005621346 *

Also Published As

Publication number Publication date
US20230002766A1 (en) 2023-01-05
CN115135765A (zh) 2022-09-30
EP4055167A2 (en) 2022-09-14
CA3160657A1 (en) 2021-05-14
WO2021092464A2 (en) 2021-05-14
WO2021092464A3 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JP7820909B2 (ja) 化学修飾されたオリゴヌクレオチド
JP6983752B2 (ja) スーパーオキシドディスムターゼ１（ｓｏｄ１）を標的とする核酸分子
JP2020114866A (ja) 遺伝子調節アプローチを用いた円形脱毛症の処置方法
CN109563509B (zh) 靶向长非编码rna的减小尺寸的自递送核酸化合物
US10808247B2 (en) Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
JP2023501445A (ja) 免疫治療のためのブロモドメイン含有タンパク質４（ｂｒｄ４）を標的とする化学修飾されたオリゴヌクレオチド
US20240301430A1 (en) Chemically modified oligonucleotides
WO2023130021A1 (en) Chemically modified oligonucleotides with improved delivery properties
US20230089478A1 (en) Chemically modified oligonucleotides with improved systemic delivery
WO2023015264A1 (en) Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
US20260097120A1 (en) Induction of stem-like activated t cells
WO2025117786A1 (en) Enhanced combination immune checkpoint inhibition therapy utilizing rnai
WO2025101204A1 (en) Intratumoral targeting of pd-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20231106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260408